You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
Pulmonology
ERS 2023 | Type 2 Biomarkers as Predictive and Prognostic Tools to Guide Management
Prof. Vibeke Backer discusses the predictive and prognostic importance of the various biomarkers of type 2 inflammation in adult asthma.
Learning objectives
Discuss the components of the evolving definition of on-treatment clinical remission in asthma
Evaluate the latest data supporting achievement of on-treatment clinical remission with biologics in severe asthma patients
Understand how type 2 inflammatory biomarkers can be useful in identifying patients and managing their asthma with on-treatment clinical remission as the goal
Description
In this video highlight from the ADVENT adult asthma symposium at ERS 2023, Vibeke Backer, MD, PhD, discusses how type 2 inflammatory biomarkers can help inform treatment decisions that target clinical remission.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.